This federal Project Grant award, totaling $655,380, was provided by the Department of the Army Medical Command under the Military Medical Research and Development program (CFDA 12.420). The grant was awarded to Dignity Health's St. Joseph's Hospital and Medical Center (also known as Barrow Neurological Institute) to conduct research on maladaptive 5-HT raphe-corticolimbic plasticity underlying the development of non-motor symptoms in Parkinson's disease. The project will be performed in...
The Department of the Army Medical Command awarded a $722,545 Project Grant under the Military Medical Research and Development program (CFDA 12.420) to Dignity Health's St. Joseph's Hospital and Medical Center in San Francisco, CA. The grant will fund a 2-year research project to investigate the role of TDP-43 associated cryptic exon inclusion in C9ORF72-mediated cortical neurodegeneration. The project aims to advance understanding of the molecular mechanisms underlying neurological disorders...
The U.S. Department of Defense's Defense Health Agency awarded a $1,119,598 Project Grant to Dignity Health, doing business as St. Joseph's Hospital and Medical Center, for the research project "AD Genetic Risk as a Prognostic Factor for Cognitive Outcomes after TBI" under the Military Medical Research and Development program (CFDA 12.420). This 4-year award, effective from September 30, 2024 to September 29, 2028, will fund innovative biomedical research focused on understanding the...
This federal Project Grant award from the Defense Health Agency, under the Military Medical Research and Development program (CFDA 12.420), provides $1,487,072.00 to Dignity Health's St. Joseph's Hospital and Medical Center in Phoenix, AZ to develop a novel bifunctional agent as a radiosensitizer for glioblastoma and a radioprotector of normal brain. The award has an initial term from August 15, 2024 to August 14, 2027. The key products or services to be delivered through this funding include...
This $1,199,967 Project Grant awarded on September 1, 2023 by the Defense Health Agency supports research under the Military Medical Research and Development (CFDA 12.420) program. The primary award recipient, the University of Vermont & State Agricultural College, will investigate "Cognitive Functions Impairment as a Novel Paradigm for Delineating Cognitive Dysfunction in Parkinson's Disease". Two sub-awards were made to Case Western Reserve University and the Portland VA Research...
This $2,000,000 Project Grant, awarded by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports research on the interrelationship between the PINK1-PRKN pathway disruption and tauopathy in the pathophysiology of cognitive impairment in Parkinson's disease. The award, with a performance period from June 1, 2025 to May 31, 2028, was granted to the Board of Regents of the University of Nebraska, through its University of Nebraska Medical...
This federal Project Grant award of $1,021,409.00 from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program will support research at the University of Illinois to investigate the underlying neurobiology of non-motor symptoms in Parkinson's disease. The research aims to elucidate the role of serotonin system plasticity in the development of these disabling non-motor complications, which can include cognitive, psychiatric, and...
This federal Project Grant award of $673,448.00, provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program, supports advanced biomedical research focused on transforming healthcare for military service members and the broader public. The award was granted to The Research Foundation For The State University Of New York (RF SUNY) to conduct research on the "MALADAPTIVE 5-HT RAPHE-CORTICOLIMBIC PLASTICITY UNDERLYING THE...
This federal Project Grant award in the amount of $811,942 was provided by the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) program. The grant supports research by the J. David Gladstone Institutes, a non-profit biomedical research organization, to investigate genetic factors conferring susceptibility to toxicant-induced Parkinson's disease. The research involves a sub-award to the Northern California Institute For Research And...
This federal Project Grant award of $325,142, provided by the Defense Health Agency under the Military Medical Research and Development (CFDA 12.420) program, supports the development of a clinical-grade spinal cord neuroprosthesis to alleviate locomotor deficits in people with Parkinson's disease. The award, which has a performance period from September 1, 2025 to August 31, 2028, is being provided to Onward Medical Inc., a for-profit organization located in Boston, MA. The goal of this...